WO2023008498A1 - 非ラメラ液晶形成性組成物及びその用途 - Google Patents
非ラメラ液晶形成性組成物及びその用途 Download PDFInfo
- Publication number
- WO2023008498A1 WO2023008498A1 PCT/JP2022/029014 JP2022029014W WO2023008498A1 WO 2023008498 A1 WO2023008498 A1 WO 2023008498A1 JP 2022029014 W JP2022029014 W JP 2022029014W WO 2023008498 A1 WO2023008498 A1 WO 2023008498A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fatty acid
- liquid crystal
- glycol
- lamellar liquid
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 271
- 239000007788 liquid Substances 0.000 title claims abstract description 112
- -1 fatty acid ester Chemical class 0.000 claims abstract description 154
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 136
- 239000000194 fatty acid Substances 0.000 claims abstract description 136
- 229930195729 fatty acid Natural products 0.000 claims abstract description 136
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 73
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 59
- 150000003839 salts Chemical class 0.000 claims abstract description 47
- 239000004973 liquid crystal related substance Substances 0.000 claims description 114
- 238000009472 formulation Methods 0.000 claims description 79
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 78
- 239000002243 precursor Substances 0.000 claims description 78
- 150000001875 compounds Chemical class 0.000 claims description 72
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 68
- 150000004665 fatty acids Chemical class 0.000 claims description 40
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 28
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 28
- 125000005480 straight-chain fatty acid group Chemical group 0.000 claims description 28
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 claims description 27
- 229960002479 isosorbide Drugs 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 26
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical group CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 26
- 229960004338 leuprorelin Drugs 0.000 claims description 26
- 108010000817 Leuprolide Proteins 0.000 claims description 25
- 239000012736 aqueous medium Substances 0.000 claims description 25
- 239000000839 emulsion Substances 0.000 claims description 25
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 18
- 229920006395 saturated elastomer Polymers 0.000 claims description 17
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 16
- 239000003960 organic solvent Substances 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 238000013268 sustained release Methods 0.000 claims description 16
- 239000012730 sustained-release form Substances 0.000 claims description 16
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 claims description 14
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 claims description 13
- 150000002430 hydrocarbons Chemical group 0.000 claims description 13
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 13
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 12
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 11
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 10
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 10
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 10
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- 102000002322 Egg Proteins Human genes 0.000 claims description 8
- 108010000912 Egg Proteins Proteins 0.000 claims description 8
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 8
- 235000013345 egg yolk Nutrition 0.000 claims description 8
- 210000002969 egg yolk Anatomy 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 8
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 6
- 235000021313 oleic acid Nutrition 0.000 claims description 6
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 5
- 235000021357 Behenic acid Nutrition 0.000 claims description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 5
- 239000005642 Oleic acid Substances 0.000 claims description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 5
- 235000021314 Palmitic acid Nutrition 0.000 claims description 5
- 229940116226 behenic acid Drugs 0.000 claims description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 5
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 4
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 4
- 239000005639 Lauric acid Substances 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 229960002446 octanoic acid Drugs 0.000 claims description 4
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 23
- 238000005259 measurement Methods 0.000 description 22
- 239000003921 oil Substances 0.000 description 21
- 235000019198 oils Nutrition 0.000 description 21
- 239000012071 phase Substances 0.000 description 21
- 239000002253 acid Substances 0.000 description 19
- 239000000499 gel Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 14
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 238000000235 small-angle X-ray scattering Methods 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 11
- 230000002441 reversible effect Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 239000008215 water for injection Substances 0.000 description 9
- PHDVPEOLXYBNJY-KTKRTIGZSA-N 2-(2-hydroxyethoxy)ethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOCCO PHDVPEOLXYBNJY-KTKRTIGZSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- ZVTDEEBSWIQAFJ-KHPPLWFESA-N 2-hydroxypropyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C)O ZVTDEEBSWIQAFJ-KHPPLWFESA-N 0.000 description 7
- QMCRGOJVEJJFKM-NBTZWHCOSA-N CC(O)CO.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O Chemical compound CC(O)CO.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O QMCRGOJVEJJFKM-NBTZWHCOSA-N 0.000 description 7
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 7
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 7
- 229940093471 ethyl oleate Drugs 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 6
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 150000002334 glycols Chemical class 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 6
- 229920001983 poloxamer Polymers 0.000 description 6
- 229920001451 polypropylene glycol Polymers 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 5
- NNUYLXMUBLHTOL-KVVVOXFISA-N CC(O)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound CC(O)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O NNUYLXMUBLHTOL-KVVVOXFISA-N 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 5
- 229940031016 ethyl linoleate Drugs 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000008159 sesame oil Substances 0.000 description 5
- 235000011803 sesame oil Nutrition 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 4
- ODDSXTDNXBAVPQ-UHFFFAOYSA-N 1,2-dihydroxypropyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(O)C(C)O ODDSXTDNXBAVPQ-UHFFFAOYSA-N 0.000 description 4
- VCNPGCHIKPSUSP-UHFFFAOYSA-N 2-hydroxypropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(C)O VCNPGCHIKPSUSP-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- HJJZFSVYWJHHFE-UHFFFAOYSA-N docosanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O HJJZFSVYWJHHFE-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 159000000003 magnesium salts Chemical class 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000001593 sorbitan monooleate Substances 0.000 description 4
- 235000011069 sorbitan monooleate Nutrition 0.000 description 4
- 229940035049 sorbitan monooleate Drugs 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 231100000827 tissue damage Toxicity 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 238000002674 endoscopic surgery Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000002357 laparoscopic surgery Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- DRAWQKGUORNASA-UHFFFAOYSA-N (2-hydroxy-3-octadec-9-enoyloxypropyl) octadec-9-enoate Chemical compound CCCCCCCCC=CCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCC=CCCCCCCCC DRAWQKGUORNASA-UHFFFAOYSA-N 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- KKNRLFRQWDXUQD-HZJYTTRNSA-N 2-hydroxyethyl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCCO KKNRLFRQWDXUQD-HZJYTTRNSA-N 0.000 description 2
- OAOABCKPVCUNKO-UHFFFAOYSA-N 8-methyl Nonanoic acid Chemical compound CC(C)CCCCCCC(O)=O OAOABCKPVCUNKO-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229920005682 EO-PO block copolymer Polymers 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000021319 Palmitoleic acid Nutrition 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 125000005313 fatty acid group Chemical group 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- YYVJAABUJYRQJO-UHFFFAOYSA-N isomyristic acid Chemical compound CC(C)CCCCCCCCCCC(O)=O YYVJAABUJYRQJO-UHFFFAOYSA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 230000002535 lyotropic effect Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 239000010913 used oil Substances 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 1
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- UNSRRHDPHVZAHH-YOILPLPUSA-N (5Z,8Z,11Z)-icosatrienoic acid Chemical compound CCCCCCCC\C=C/C\C=C/C\C=C/CCCC(O)=O UNSRRHDPHVZAHH-YOILPLPUSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 description 1
- XUJWOMMOEOHPFP-UHFFFAOYSA-N (all-Z)-8,11-Eicosadienoic acid Natural products CCCCCCCCC=CCC=CCCCCCCC(O)=O XUJWOMMOEOHPFP-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- ZONJATNKKGGVSU-UHFFFAOYSA-N 14-methylpentadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCC(O)=O ZONJATNKKGGVSU-UHFFFAOYSA-N 0.000 description 1
- UCDAVJCKGYOYNI-UHFFFAOYSA-N 18-methylnonadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCCCC(O)=O UCDAVJCKGYOYNI-UHFFFAOYSA-N 0.000 description 1
- MKDWBKQJTQIVRJ-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCCOCCO MKDWBKQJTQIVRJ-UHFFFAOYSA-N 0.000 description 1
- RGODSEMCBFJLCL-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCOCCO RGODSEMCBFJLCL-UHFFFAOYSA-N 0.000 description 1
- NDYHDTGNPTWQMI-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl octanoate Chemical compound CCCCCCCC(=O)OCCOCCO NDYHDTGNPTWQMI-UHFFFAOYSA-N 0.000 description 1
- LZSVYIQKUAVZFB-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCOCCO LZSVYIQKUAVZFB-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HJIHXGNKBCJVAR-UHFFFAOYSA-N 2-hydroxyethyl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCCO HJIHXGNKBCJVAR-UHFFFAOYSA-N 0.000 description 1
- BXCRLBBIZJSWNS-UHFFFAOYSA-N 2-hydroxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCO BXCRLBBIZJSWNS-UHFFFAOYSA-N 0.000 description 1
- CBLFQQQLPYAQCP-UHFFFAOYSA-N 2-hydroxyethyl octanoate Chemical compound CCCCCCCC(=O)OCCO CBLFQQQLPYAQCP-UHFFFAOYSA-N 0.000 description 1
- ABFWOTZXBYVPIF-UHFFFAOYSA-N 2-hydroxyethyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCO ABFWOTZXBYVPIF-UHFFFAOYSA-N 0.000 description 1
- UKKNMCFZDIOGAW-KTKRTIGZSA-N 4-hydroxybutyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCCO UKKNMCFZDIOGAW-KTKRTIGZSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- UNSRRHDPHVZAHH-UHFFFAOYSA-N 6beta,11alpha-Dihydroxy-3alpha,5alpha-cyclopregnan-20-on Natural products CCCCCCCCC=CCC=CCC=CCCCC(O)=O UNSRRHDPHVZAHH-UHFFFAOYSA-N 0.000 description 1
- XZOYHFBNQHPJRQ-UHFFFAOYSA-N 7-methyloctanoic acid Chemical compound CC(C)CCCCCC(O)=O XZOYHFBNQHPJRQ-UHFFFAOYSA-N 0.000 description 1
- XUJWOMMOEOHPFP-OKLKQMLOSA-N 8,11-Eicosadienoic acid Chemical compound CCCCCCCC\C=C\C\C=C\CCCCCCC(O)=O XUJWOMMOEOHPFP-OKLKQMLOSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- CWKVPNUOHOFFMS-UHFFFAOYSA-N C(CCCCCCCCCCCCC)(=O)O.C(CC(C)O)O Chemical compound C(CCCCCCCCCCCCC)(=O)O.C(CC(C)O)O CWKVPNUOHOFFMS-UHFFFAOYSA-N 0.000 description 1
- SXYFFDPJERXIAV-UHFFFAOYSA-N CC(O)CCO.CCCCCCCCCCCCCCCC(O)=O Chemical compound CC(O)CCO.CCCCCCCCCCCCCCCC(O)=O SXYFFDPJERXIAV-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000284156 Clerodendrum quadriloculare Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- 229920003115 HPC-SL Polymers 0.000 description 1
- 229920003116 HPC-SSL Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000005643 Pelargonic acid Substances 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 235000021322 Vaccenic acid Nutrition 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 1
- JCABVIFDXFFRMT-DIPNUNPCSA-N [(2r)-1-[ethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC)OC(=O)CCCCCCCC=CCCCCCCCC JCABVIFDXFFRMT-DIPNUNPCSA-N 0.000 description 1
- TTZKGYULRVDFJJ-GIVMLJSASA-N [(2r)-2-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-[(z)-octadec-9-enoyl]oxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1O TTZKGYULRVDFJJ-GIVMLJSASA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- CUXYLFPMQMFGPL-SUTYWZMXSA-N all-trans-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-SUTYWZMXSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- KDBHXVFZVDTLRJ-UHFFFAOYSA-N butane-1,3-diol;octanoic acid Chemical compound CC(O)CCO.CCCCCCCC(O)=O KDBHXVFZVDTLRJ-UHFFFAOYSA-N 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 229960001590 butorphanol tartrate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229920003112 high viscosity grade hydroxypropyl cellulose Polymers 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- SIOLDWZBFABPJU-UHFFFAOYSA-N isotridecanoic acid Chemical compound CC(C)CCCCCCCCCC(O)=O SIOLDWZBFABPJU-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004882 medetomidine hydrochloride Drugs 0.000 description 1
- VPNGEIHDPSLNMU-UHFFFAOYSA-N medetomidine hydrochloride Chemical compound Cl.C=1C=CC(C)=C(C)C=1C(C)C1=CNC=N1 VPNGEIHDPSLNMU-UHFFFAOYSA-N 0.000 description 1
- 229920003117 medium viscosity grade hydroxypropyl cellulose Polymers 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 229940074096 monoolein Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 210000000505 parietal peritoneum Anatomy 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XWIHRGFIPXWGEF-UHFFFAOYSA-N propafenone hydrochloride Chemical compound Cl.CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 XWIHRGFIPXWGEF-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
[1] 脂肪酸エステルと、リン脂質とを含み、
前記脂肪酸エステルが、1つの水酸基又はその塩を有する親水性基を有し、
前記脂肪酸エステルが、下記一般式(A)~(D)で表されるいずれの構造も有さない脂肪酸エステルである、非ラメラ液晶形成性組成物。
[2] 前記脂肪酸エステルの脂肪酸の炭素数が6~24である、[1]に記載の組成物。
[3] 前記脂肪酸エステルと前記リン脂質との重量比が、90:10~20:80である、[1]又は[2]に記載の組成物。
[4] 前記脂肪酸エステルが、飽和又は不飽和の直鎖脂肪酸及びその誘導体から選択される少なくとも1種と、グリコール及びその誘導体から選択される少なくとも1種との脂肪酸エステルである、[1]~[3]のいずれか1つに記載の組成物。
[6] 前記直鎖脂肪酸が下記一般式(I)で表される直鎖脂肪酸である、[4]又は[5]に記載の組成物。
[7] 前記直鎖脂肪酸がカプリル酸、ラウリン酸、ミリスチン酸、パルミチン酸、オレイン酸、リノール酸、及びベヘン酸から選択される少なくとも1種の脂肪酸である、[4]~[6]のいずれか1つに記載の組成物。
[8] 前記グリコールがプロピレングリコール、エチレングリコール、ブチレングリコール、3-メチル-1,3-ブタンジオール、ジエチレングリコール、及びイソソルバイドから選択される少なくとも1種のグリコールである、[4]~[7]のいずれか1つに記載の組成物。
[9] 前記リン脂質がホスファチジルコリン及びホスファチジルエタノールアミン並びにそれらの塩から選択される少なくとも1種のリン脂質である、[1]~[8]のいずれか1つに記載の組成物。
[10] 前記リン脂質が大豆ホスファチジルコリン、卵黄ホスファチジルコリン、ジミリストイルホスファチジルコリン、ジオレイルホスファチジルコリン、及びジオレイルホスファチジルエタノールアミン並びにそれらの塩から選択される少なくとも1種のリン脂質である、[1]~[9]のいずれか1つに記載の組成物。
[11] 油分及び有機溶媒の少なくとも一方を含む、[1]~[10]のいずれか1つに記載の組成物。
[12] 水性媒体をさらに含む、非ラメラ液晶組成物である、[1]~[11]のいずれか1つに記載の組成物。
[13] 界面活性剤をさらに含む、非ラメラ液晶エマルション組成物である、[12]に記載の組成物。
[14] 水性媒体の存在下で非ラメラ液晶を形成可能である液晶前駆体組成物である、[1]~[11]のいずれか1つに記載の組成物。
[16] 生体組織の癒着防止用の、[15]に記載の医薬製剤。
[17] 前記組成物が薬物をさらに含む、徐放性製剤である[15]に記載の医薬製剤。
[18] 前記薬物が、ゴナドトロピン放出ホルモン(GnRH)アゴニストである、[17]に記載の医薬製剤。
[19] 前記GnRHアゴニストが、ロイプロリド又はその塩である、[18]に記載の医薬製剤。
[20] スプレー剤、エアゾール剤、注射剤、又はデポ剤である、[15]~[19]のいずれか1つに記載の医薬製剤。
[21] 式(X’)で表される化合物又はその塩。
[22] 式(X)、(Y)、又は(Z)で表される化合物又はその塩。
モノカプリル酸プロピレングリコール、
モノオレイン酸プロピレングリコール、
モノミリスチン酸プロピレングリコール、
モノパルミチン酸プロピレングリコール、
モノリノール酸プロピレングリコール、
モノベヘン酸プロピレングリコール、
モノカプリル酸エチレングリコール、
モノオレイン酸エチレングリコール、
モノミリスチン酸エチレングリコール、
モノパルミチン酸エチレングリコール、
モノリノール酸エチレングリコール、
モノベヘン酸エチレングリコール、
モノカプリル酸1,3-ブチレングリコール、
モノオレイン酸1,3-ブチレングリコール、
モノミリスチン酸1,3-ブチレングリコール、
モノパルミチン酸1,3-ブチレングリコール、
モノリノール酸1,3-ブチレングリコール、
モノベヘン酸1,3-ブチレングリコール、
モノカプリル酸3-メチル-1,3-ブタンジオール、
モノオレイン酸3-メチル-1,3-ブタンジオール、
モノミリスチン酸3-メチル-1,3-ブタンジオール、
モノパルミチン酸3-メチル-1,3-ブタンジオール、
モノリノール酸3-メチル-1,3-ブタンジオール、
モノベヘン酸3-メチル-1,3-ブタンジオール、
モノカプリル酸ジエチレングリコール、
モノオレイン酸ジエチレングリコール、
モノミリスチン酸ジエチレングリコール、
モノパルミチン酸ジエチレングリコール、
モノリノール酸ジエチレングリコール、
モノベヘン酸ジエチレングリコール、
モノカプリル酸イソソルバイド、
モノオレイン酸イソソルバイド、
モノミリスチン酸イソソルバイド、
モノパルミチン酸イソソルバイド、
モノリノール酸イソソルバイド、
モノベヘン酸イソソルバイド、
が挙げられ、別の例としては、前述の脂肪酸エステルが有する親水性基が有する水酸基が塩になったものが挙げられるがこれらに限定されるものではない。水酸基の塩としては、好ましくは、水酸基のナトリウム塩(-ONa)、水酸基のカリウム塩(-OK)、水酸基のカルシウム塩(-OCa1/2)、水酸基のマグネシウム塩(-OMg1/2)、それ以外の製薬上許容される塩が挙げられる。
モノオレイン酸プロピレングリコール、
モノリノール酸プロピレングリコール、
モノオレイン酸エチレングリコール、
モノリノール酸エチレングリコール、
モノオレイン酸1,3-ブチレングリコール、
モノリノール酸1,3-ブチレングリコール、
モノオレイン酸3-メチル-1,3-ブタンジオール、
モノリノール酸3-メチル-1,3-ブタンジオール、
モノオレイン酸ジエチレングリコール、
モノリノール酸ジエチレングリコール、
モノオレイン酸イソソルバイド、
モノリノール酸イソソルバイド、
が挙げられ、別の例としては、前述の脂肪酸エステルが有する親水性基が有する水酸基が塩になったものが挙げられるがこれらに限定されるものではない。水酸基の塩としては、好ましくは、水酸基のナトリウム塩(-ONa)、水酸基のカリウム塩(-OK)、水酸基のカルシウム塩(-OCa1/2)、水酸基のマグネシウム塩(-OMg1/2)、それ以外の製薬上許容される塩が挙げられる。
Pn3mキュービック液晶の比:
√2:√3:√4:√6:√8:√9:√10: ,,,,
Ia3dキュービック液晶の比:
√3:√4:√7:√8:√10:√11: ,,,,
Im3mキュービック液晶の比:
√2:√4:√6:√8:√10:√12:√14: ,,,,
Fd3mキュービック液晶の比:
√3:√8:√11:√12:√16:√19:√24:√27: ,,,,
逆ヘキサゴナル液晶に特有の比:
1:√3:2: ,,,,
また当業者に周知の方法に従って、SAXSの強度分布データからピークの値を算出し、さらにそれらの逆数の比を求めれば容易に空間群と格子定数を決めることができる。
・グレード1 軽い牽引で剥離可能な癒着(組織損傷を伴わない)
・グレード2 強い牽引で剥離可能な癒着(組織損傷を伴わない)
・グレード3 強い牽引の剥離により組織損傷を伴う癒着
非ラメラ液晶形成性組成物サンプル適用切開部において、同一動物個体の非適用切開部と比較して評価スコアが低い場合、癒着防止効果が認められると判断することができる。
(1)モノオレイン酸プロピレングリコールの合成
後掲の表1及び表2に示す配合比に従って、親水性基が1つの水酸基を有する両親媒性化合物(脂肪酸エステル)として実施例1で合成した両親媒性化合物又はモノカプリル酸(C8:0)プロピレングリコール(モノカプリル酸プロピレングリコール)(NIKKOL SEFSOL-218、日光ケミカルズ株式会社)、リン脂質として大豆ホスファチジルコリン(大豆レシチン、LIPOID S100、リポイド社。以下及び表中では略称SPCを使用)、卵黄ホスファチジルコリン(精製卵黄レシチン、PL-100M、キューピー株式会社。以下及び表中では略称EPCを使用)、又はジオレイルホスファチジルエタノールアミン(COATSOME ME-8181、日油株式会社。以下及び表中では略称DOPEを使用)、油分としてゴマ油(トリグリセリド、日本薬局方ゴマ油、カネダ株式会社)、及びEtOH(エタノール)を混合した。得られた混合物を40℃以下の水浴中で溶解することによって、表1、2に示すNo.1~23の前駆体製剤を調製した。
後掲の表3に示す配合比に従って、親水性基が1つの水酸基を有する両親媒性化合物としてモノオレイン酸(C18:1)プロピレングリコール(実施例1で合成)、リン脂質としてSPC、油分としてゴマ油、及びEtOHを混合して、油性溶液を得た。一方、界面活性剤としてプルロニックF127(ユニルーブ(登録商標)70DP-950B、日油株式会社)と注射用水(大塚蒸留水)を混合して、プルロニック水溶液を得た。このようにして調製した油性溶液とプルロニック水溶液をそれぞれ40℃以下の水浴中で完全に溶解した後、室温で1つに混合し薬匙又はスターラーチップで撹拌して、懸濁液とした。さらに、この懸濁液を高圧ホモジナイザー(スターバストminimo、スギノマシン製)で分散させることによって、微粒子を含有する白色のエマルション(製剤No.24及び25)を調製した。これらエマルションは、それぞれ8gの量で調製した。
親水性基が1~3つの水酸基を有する両親媒性化合物において、リン脂質を有する前駆体製剤の特性を比較した。
後掲の表5に示す配合比に従って、親水性基が1つの水酸基を有する両親媒性化合物としてモノオレイン酸(C18:1)プロピレングリコール、リン脂質としてSPC、油分としてゴマ油、及びEtOHを混合した後、40℃以下の水浴中で溶解した。続いて、酢酸ロイプロリド(L0249、東京化成工業株式会社、以下及び表中では略称LAを使用)のジメチルスルホキシド(DMSO)溶液を添加し均一に溶解することによって、酢酸ロイプロリドを配合した前駆体製剤No.32~35を得た。
・移動相;水(0.1%ギ酸含有):アセトニトリル=70:30
・流速;0.1mL/min、カラム温度;40℃、注入量;10μL
・プリカーサーイオン;605.3m/z,プロダクトイオン;249.0m/z
予め頸静脈にカニュレーションを施した8週齢雄Wistarラットに対し三種混合麻酔(塩酸メデトミジン+ミダゾラム+酒石酸ブトルファノール)を用いて全身麻酔を施行し、背部を剃毛した後、酢酸ロイプロリドを配合した前駆体製剤No.34及び35(実施例5で調製)各100mgについて、23Gの針を備えたシリンジ(テルモシリンジ1mL)を用いて右背部の皮下に投与した。
収量2.67g(収率76%)
1H-NMRスペクトル(300MHz,CDCl3,TMS)δ:0.89(m,3H),1.2-1.4(m,17H),1.62(m,2H),1.6-1.9(m,2H),1.95-2.1(m,4H),2.30-2.37(m,2H),2.77(m,2H),3.5-3.7(m,0.5H),3.85(m,0.75H),4.12(m,0.75H),4.35(ddd,J=5.3,8.3,13.6Hz,0.75H),5.13(m,0.25H),5.26-5.44(m,4H)
1H-NMRスペクトル(300MHz,CDCl3,TMS)δ:0.89(m,3H),1.2-1.4(m,20H),1.62(m,2H),1.84(t,J=6.9Hz,2H),1.95-2.1(m,4H),2.30(t,J=7.5Hz,2H),2.77(m,2H),4.25(t,J=6.9Hz,2H),5.27-5.43(m,4H)
1H-NMRスペクトル(300MHz,CDCl3,TMS)δ:0.89(m,3H),1.2-1.4(m,14H),1.63(m,2H),1.95-2.1(m,4H),2.34(t,J=7.6Hz,2H),2.77(m,2H),3.61(m,2H),3.70(m,2H),3.74(m,2H),4.25(m,2H),5.27-5.44(m,4H)
1H-NMRスペクトル(300MHz,CDCl3,TMS)δ:0.89(m,3H),1.2-1.4(m,14H),1.64(m,2H),1.95-2.1(m,4H),2.3-2.4(m,2H),2.77(m,2H),3.55(dd,J=6.0,9.5Hz,0.6H),3.75(ddd,J=2.1.5.2,9.8Hz,0.4H),3.8-3.95(m,1.8H),3.99(m,1.2H),4.2-4.35(m,1H),4.38(d,J=4.6Hz,0.4H),4.44(d,J=4.3Hz,0.6H),4.60(t,J=4.9Hz,0.6H),4.83(t,J=5.0Hz,0.4H),5.12(m,0.4H),5.21(s,0.6H),5.26-5.45(m,4H)
1H-NMRスペクトル(300MHz,CDCl3,TMS)δ:0.88(m,3H),1.2-1.4(m,20H),1.64(m,2H),1.95-2.15(m,4H),2.25-2.4(m,2H),3.54(dd,J=6.0,9.5Hz,0.6H),3.74(ddd,J=2.1.5.2,9.8Hz,0.4H),3.8-3.95(m,1.8H),3.99(m,1.2H),4.2-4.35(m,1H),4.37(d,J=4.6Hz,0.4H),4.44(d,J=4.3Hz,0.6H),4.60(t,J=4.9Hz,0.6H),4.82(t,J=5.0Hz,0.4H),5.12(m,0.4H),5.20(s,0.6H),5.34(m,2H)
後掲の表6に示す配合比に従って、実施例7で合成した両親媒性化合物、リン脂質としてSPC(LIPOID S100、リポイド社)、及びEtOH(エタノール)を混合した。得られた混合物を40℃以下の水浴中で溶解することによって、表6に示すNo.36~40の前駆体製剤を調製した。
Claims (22)
- 前記脂肪酸エステルの脂肪酸の炭素数が6~24である、請求項1に記載の組成物。
- 前記脂肪酸エステルと前記リン脂質との重量比が、90:10~20:80である、請求項1又は2に記載の組成物。
- 前記脂肪酸エステルが、飽和又は不飽和の直鎖脂肪酸及びその誘導体から選択される少なくとも1種と、グリコール及びその誘導体から選択される少なくとも1種との脂肪酸エステルである、請求項1~3のいずれか1項に記載の組成物。
- 前記直鎖脂肪酸が、不飽和度が0~6の直鎖脂肪酸である、請求項4に記載の組成物。
- 前記直鎖脂肪酸がカプリル酸、ラウリン酸、ミリスチン酸、パルミチン酸、オレイン酸、リノール酸、及びベヘン酸から選択される少なくとも1種の脂肪酸である、請求項4~6のいずれか1項に記載の組成物。
- 前記グリコールがプロピレングリコール、エチレングリコール、ブチレングリコール、3-メチル-1,3-ブタンジオール、ジエチレングリコール、及びイソソルバイドから選択される少なくとも1種のグリコールである、請求項4~7のいずれか1項に記載の組成物。
- 前記リン脂質がホスファチジルコリン及びホスファチジルエタノールアミン並びにそれらの塩から選択される少なくとも1種のリン脂質である、請求項1~8のいずれか1項に記載の組成物。
- 前記リン脂質が大豆ホスファチジルコリン、卵黄ホスファチジルコリン、ジミリストイルホスファチジルコリン、ジオレイルホスファチジルコリン、及びジオレイルホスファチジルエタノールアミン並びにそれらの塩から選択される少なくとも1種のリン脂質である、請求項1~9のいずれか1項に記載の組成物。
- 油分及び有機溶媒の少なくとも一方を含む、請求項1~10のいずれか1項に記載の組成物。
- 水性媒体をさらに含む、非ラメラ液晶組成物である、請求項1~11のいずれか1項に記載の組成物。
- 界面活性剤をさらに含む、非ラメラ液晶エマルション組成物である、請求項12に記載の組成物。
- 水性媒体の存在下で非ラメラ液晶を形成可能である液晶前駆体組成物である、請求項1~11のいずれか1項に記載の組成物。
- 請求項1~14のいずれか1項に記載の組成物を含む、医薬製剤。
- 生体組織の癒着防止用の、請求項15に記載の医薬製剤。
- 前記組成物が薬物をさらに含む、徐放性製剤である請求項15に記載の医薬製剤。
- 前記薬物が、ゴナドトロピン放出ホルモン(GnRH)アゴニストである、請求項17に記載の医薬製剤。
- 前記GnRHアゴニストが、ロイプロリド又はその塩である、請求項18に記載の医薬製剤。
- スプレー剤、エアゾール剤、注射剤、又はデポ剤である、請求項15~19のいずれか1項に記載の医薬製剤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023538607A JPWO2023008498A1 (ja) | 2021-07-27 | 2022-07-27 | |
CN202280052806.8A CN117794519A (zh) | 2021-07-27 | 2022-07-27 | 非层状液晶形成性组合物及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-122489 | 2021-07-27 | ||
JP2021122489 | 2021-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023008498A1 true WO2023008498A1 (ja) | 2023-02-02 |
Family
ID=85086981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/029014 WO2023008498A1 (ja) | 2021-07-27 | 2022-07-27 | 非ラメラ液晶形成性組成物及びその用途 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2023008498A1 (ja) |
CN (1) | CN117794519A (ja) |
WO (1) | WO2023008498A1 (ja) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10504532A (ja) * | 1994-06-15 | 1998-05-06 | ゲー・エス・デイベロツプメント・アクチエボラーグ | ジアシルグリセロール、リン脂質、極性液体および生物活性物質を含有する脂質をベースとした組成物 |
JP2014527545A (ja) | 2011-08-30 | 2014-10-16 | チョン クン ダン ファーマシューティカル コーポレーション | 薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬学的組成物 |
WO2014178256A1 (ja) * | 2013-05-01 | 2014-11-06 | 株式会社ファルネックス | 癒着防止剤 |
JP2015505833A (ja) * | 2011-12-05 | 2015-02-26 | カムルス エービー | 頑強な徐放性製剤 |
CN105613493A (zh) * | 2016-02-24 | 2016-06-01 | 深圳百乐宝生物农业科技有限公司 | 一种丙二醇单脂肪酸酯作为杀螨剂的用途和杀螨剂及应用 |
JP2018502091A (ja) | 2014-12-23 | 2018-01-25 | カムルス エービー | 制御放出製剤 |
US20180155357A1 (en) * | 2015-04-24 | 2018-06-07 | Basf Se | Isosorbide diester as pearlizing agent and opacifier |
WO2020070846A1 (ja) * | 2018-10-04 | 2020-04-09 | 竹本油脂株式会社 | ポリオレフィン系樹脂用改質剤 |
JP2021122489A (ja) | 2020-02-05 | 2021-08-30 | 株式会社コナミアミューズメント | ゲームシステム、管理システム、プログラム及びゲームシステムの動作方法 |
-
2022
- 2022-07-27 JP JP2023538607A patent/JPWO2023008498A1/ja active Pending
- 2022-07-27 WO PCT/JP2022/029014 patent/WO2023008498A1/ja active Application Filing
- 2022-07-27 CN CN202280052806.8A patent/CN117794519A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10504532A (ja) * | 1994-06-15 | 1998-05-06 | ゲー・エス・デイベロツプメント・アクチエボラーグ | ジアシルグリセロール、リン脂質、極性液体および生物活性物質を含有する脂質をベースとした組成物 |
JP2014527545A (ja) | 2011-08-30 | 2014-10-16 | チョン クン ダン ファーマシューティカル コーポレーション | 薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬学的組成物 |
JP2015505833A (ja) * | 2011-12-05 | 2015-02-26 | カムルス エービー | 頑強な徐放性製剤 |
WO2014178256A1 (ja) * | 2013-05-01 | 2014-11-06 | 株式会社ファルネックス | 癒着防止剤 |
JP2018502091A (ja) | 2014-12-23 | 2018-01-25 | カムルス エービー | 制御放出製剤 |
US20180155357A1 (en) * | 2015-04-24 | 2018-06-07 | Basf Se | Isosorbide diester as pearlizing agent and opacifier |
CN105613493A (zh) * | 2016-02-24 | 2016-06-01 | 深圳百乐宝生物农业科技有限公司 | 一种丙二醇单脂肪酸酯作为杀螨剂的用途和杀螨剂及应用 |
WO2020070846A1 (ja) * | 2018-10-04 | 2020-04-09 | 竹本油脂株式会社 | ポリオレフィン系樹脂用改質剤 |
JP2021122489A (ja) | 2020-02-05 | 2021-08-30 | 株式会社コナミアミューズメント | ゲームシステム、管理システム、プログラム及びゲームシステムの動作方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2023008498A1 (ja) | 2023-02-02 |
CN117794519A (zh) | 2024-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2632433C2 (ru) | Липидный преконцентрат с замедленным высвобождением фармакологически активного вещества и фармацевтическая композиция, содержащая его | |
JP6741655B2 (ja) | アプレピタントのエマルジョン製剤 | |
EP1545757B1 (en) | Perfluorocarbon emulsions with non-fluorinated surfactants | |
JP5127466B2 (ja) | 医薬脂質組成物 | |
AU2013371101B2 (en) | Sustained-release lipid pre-concentrate of GnRH analogues and pharmaceutical composition comprising the same | |
RU2632436C2 (ru) | Липидный преконцентрат анионных фармакологически активных веществ с замедленным высвобождением и содержащая его фармацевтическая композиция | |
EP2992910A1 (en) | Adhesion preventing agent | |
JP6050440B2 (ja) | Dhaエステルを含む非経口投与のための医薬組成物 | |
CN105919949B (zh) | 一种稳定的氟比洛芬酯冻干乳及其制备方法 | |
WO2023008498A1 (ja) | 非ラメラ液晶形成性組成物及びその用途 | |
KR100654102B1 (ko) | 유용성 생리활성성분이 함입된 안정도가 우수한 산성도민감성 고분자-리포좀 나노복합체의 제조 및 이를 함유하는화장품 조성물 | |
EP4173614A1 (en) | Injectable composition comprising gnrh derivatives | |
CN112190504B (zh) | 一种含有玫瑰精油的长效液体凝胶及其制备方法和应用 | |
WO2021153635A1 (ja) | 安全性の高い非ラメラ液晶形成性組成物 | |
RU2448731C2 (ru) | Фосфолипидная композиция | |
US20220313669A1 (en) | Emulsions for local anesthetics | |
JP2616240B2 (ja) | 脂肪乳剤の製法 | |
CN1903177A (zh) | 前列地尔纳米粒及其制备方法 | |
JP2013203680A (ja) | ビタミンe誘導体を含有する血中滞留性薬物キャリアー粒子 | |
JP2009502764A (ja) | 担体と有効成分の分子間結合錯体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22849559 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023538607 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022849559 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022849559 Country of ref document: EP Effective date: 20240227 |